<div id="readability-page-1"><div><p>As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money.  So let's look at two noteworthy recent insider buys.</p><p>At Robinhood Markets, a filing with the SEC revealed that on Thursday, Director Meyer Malka bought 249,000 shares of HOOD, for a cost of $80.39 each, for a total investment of $20.02M.  So far Malka is in the green, up about 11.0% on their buy based on today's trading high of $89.20.  Robinhood Markets is trading off about 3.5% on the day Tuesday.  This buy marks the first one filed by Malka in the past twelve months. </p><p>And at Outlook Therapeutics, there was insider buying on Thursday, by  Ghiath M. Sukhtian who purchased 8,539,709 shares at a cost of $0.59 each, for a total investment of $5M.  Outlook Therapeutics Inc is trading up about 0.8% on the day Tuesday.  So far Sukhtian is in the green, up about 56.1% on their purchase based on today's trading high of $0.91. </p><p><img height="30" src="https://imageproxy.pbkrs.com/http://www.marketnewsvideo.com/previews/202606/20260602insiderHOODOsm.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="40" original-src="https://imageproxy.pbkrs.com/http://www.marketnewsvideo.com/previews/202606/20260602insiderHOODOsm.jpg"/><b>VIDEO: Tuesday 6/2 Insider Buying Report: HOOD, OTLK</b></p> <p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p> </div></div>

OTLK

HOOD

<p>Insider buying reports for Tuesday, June 2 highlight significant purchases at Robinhood Markets (HOOD) and Outlook Therapeutics (OTLK). Robinhood Director Meyer Malka bought 249,000 shares for $20.02M, currently up 11%. Outlook Therapeutics executive Ghiath M. Sukhtian purchased over 8.5 million shares for $5M, seeing a 56.1% gain based on recent highs.</p>